Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with psoriasis

Br J Clin Pharmacol. 1996 May;41(5):421-4. doi: 10.1046/j.1365-2125.1996.33311.x.

Abstract

Eight patients with psoriasis were given 200 mg caffeine orally with or without 1.2 mg kg-1 of 5-methoxypsoralen. Blood and urine samples were collected over a 2-day period. During 5-methoxypsoralen coadministration, the apparent volume of distribution of caffeine remained unchanged, but oral clearance (CLp.o.) decreased from 9.5 +/- 3.8 (mean +/- s.d.) to 3.2 +/- 0.51 h-1 (P < 0.01). The area under the plasma concentration-time curve (AUC) increased from 24 +/- 9 to 73 +/- 29 mg 1(-1) h (P < 0.001). This decrease in CLp.o. with increased AUC was consistent with a CYP1A2-dependent inhibition of caffeine N-demethylation which was further supported by significant decreases in the (AFMU+1U+1X)/17U and (AFMU+1U+1X)/17X urinary metabolic ratios.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 5-Methoxypsoralen
  • Adult
  • Aged
  • Caffeine / blood
  • Caffeine / metabolism*
  • Caffeine / urine
  • Central Nervous System Stimulants / blood
  • Central Nervous System Stimulants / metabolism*
  • Central Nervous System Stimulants / urine
  • Female
  • Humans
  • Male
  • Methoxsalen / analogs & derivatives*
  • Methoxsalen / blood
  • Methoxsalen / pharmacology
  • Methoxsalen / urine
  • Middle Aged
  • Psoriasis / drug therapy*

Substances

  • Central Nervous System Stimulants
  • Caffeine
  • 5-Methoxypsoralen
  • Methoxsalen